Want to see INAB full AI Analyst Report?
INAB Stock Chart & Stats
$1.44
-$0.04(-11.59%)
At close: 4:00 PM EST
$1.44
-$0.04(-11.59%)
Day’s Range― - ―
52-Week Range$1.17 - $2.73
Previous CloseN/A
Volume363.43K
Average Volume (3M)44.77K
Market Cap
$12.41M
Enterprise Value$9.22
Total Cash (Recent Filing)$21.94M
Total Debt (Recent Filing)$2.35M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 06, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.76
Shares Outstanding9,847,089
10 Day Avg. Volume67,462
30 Day Avg. Volume44,767
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.37
Price to Sales (P/S)0.00
P/FCF Ratio-0.81
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside247.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.24
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data Momentum (glioblastoma)Robust GBM Phase 1/2 results showing large PFS gains, improving OS and a clean safety profile materially raise the program's probability of advancing regulatory discussions, attracting partners, and enabling future pivotal strategies. That clinical durability supports long-term value creation beyond short-term market moves.
Low Leverage, Falling DebtVery low leverage and declining absolute debt reduce bankruptcy and refinancing risk, giving management structural financial flexibility. Conservative debt levels help preserve optionality for R&D and partnering talks, improving resilience during multi-year clinical development cycles.
Capital-raising Flexibility (ATM Program)An ATM facility creates durable financing optionality: management can raise equity on a controlled basis to fund development without negotiating bespoke deals. This structural access to capital reduces the immediacy of liquidity risk and supports multi-stage clinical programs.
Bears Say
No Commercial RevenueAbsent product sales, the business depends entirely on financing and partnerships; this eliminates internal revenue cushions and makes long-term sustainability contingent on successful trials or deals. That structural lack of recurring revenue raises execution and dilution risk over months to years.
Sustained Negative Cash GenerationPersistent negative operating and free cash flow means the company cannot self-fund development. Even with burn improvement, ongoing negative cash generation forces repeated capital raises or partnerships, creating execution uncertainty and potential shareholder dilution over the medium term.
Shrinking Shareholders' EquityMaterial decline in equity reduces the balance-sheet buffer available for setbacks and increases reliance on external capital. Shrinking equity combined with negative retained earnings heightens the likelihood of dilution or constrained strategic options during critical clinical inflection points.
IN8bio News
INAB FAQ
What was In8bio, Inc.’s price range in the past 12 months?
In8bio, Inc. lowest stock price was $1.17 and its highest was $2.73 in the past 12 months.
What is In8bio, Inc.’s market cap?
In8bio, Inc.’s market cap is $12.41M.
When is In8bio, Inc.’s upcoming earnings report date?
In8bio, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 14 days.
How were In8bio, Inc.’s earnings last quarter?
In8bio, Inc. released its earnings results on May 07, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.618 by $0.358.
Is In8bio, Inc. overvalued?
According to Wall Street analysts In8bio, Inc.’s price is currently Undervalued.
Does In8bio, Inc. pay dividends?
In8bio, Inc. does not currently pay dividends.
What is In8bio, Inc.’s EPS estimate?
In8bio, Inc.’s EPS estimate is -0.34.
How many shares outstanding does In8bio, Inc. have?
In8bio, Inc. has 9,847,089 shares outstanding.
What happened to In8bio, Inc.’s price movement after its last earnings report?
In8bio, Inc. reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.618. Following the earnings report the stock price went down -1.25%.
Which hedge fund is a major shareholder of In8bio, Inc.?
Currently, no hedge funds are holding shares in INAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
In8bio, Inc.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation. Further development includes preclinical programs, INB-400 and INB-300, which are designed to address a range of solid tumor cancers. Established in 2016, the company initially operated as Incysus Therapeutics, Inc. before changing its name to IN8bio, Inc. in August 2020. Its corporate headquarters are located in New York, New York.
INAB Stock 12 Month Forecast
Average Price Target
$5.00
▲(247.22% Upside)
Technical Analysis
Eterna Therapeutics
―
Quoin Pharmaceuticals
―
Xenetic Biosciences
―
VYNE Therapeutics
―
Aprea Therapeutics
―
Ownership Overview
5.04% Insiders
4.50% Mutual Funds
25.63% Other Institutional Investors
63.93% Public Companies and
Individual Investors